For GenMark, more flu was good news in 2012

Thanks in part to a really nasty flu season, GenMark Diagnostics ($GNMK) ended 2012 with a big boost in revenue. The Carlsbad, CA, company generated $9.4 million in revenue for the 2012 fourth quarter, up substantially from $2 million in revenue over the same period a year ago. For the year, GenMark booked nearly $20.5 million in revenue, a big jump from the company's $5 million in revenue generated in 2011. GenMark's $21.9 million in net losses for the year were still high, but an improvement over nearly $24 million in net losses over the previous year. GenMark's four FDA-cleared molecular diagnostic tests focus on cystic fibrosis genotyping, respiratory viruses, thrombophilia and sensitivity to warfarin. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.